IGF status is altered by tamoxifen in patients with breast cancer

Marion Campbell, Jayne Woodside, J. Secker-Walker, A. Titcomb, Claire Leathem

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aims-An increased concentration of insulin-like growth factor 1 (IGF-1) is an independent risk factor for premenopausal breast cancer. Tamoxifen is thought initially to reduce concentrations of IGF-1 and increase concentrations of the IGF binding proteins. The aim of this study was to compare concentrations of IGF-1, IGF binding protein 1 (IGF-BP1), and IGF-BP3 in patients with breast cancer (n = 14) with those seen in control subjects (n = 23) and to assess the effect of tamoxifen on IGF status in these patients.
Original languageEnglish
Pages (from-to)307-310
Number of pages4
JournalJOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY
Volume54
Issue number5
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'IGF status is altered by tamoxifen in patients with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Campbell, M., Woodside, J., Secker-Walker, J., Titcomb, A., & Leathem, C. (2001). IGF status is altered by tamoxifen in patients with breast cancer. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 54(5), 307-310.